Sphingolipids, ABC transporters and chemosensitivity in neuroblastoma by Dijkhuis, Anne-Jan
  
 University of Groningen
Sphingolipids, ABC transporters and chemosensitivity in neuroblastoma
Dijkhuis, Anne-Jan
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2006
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Dijkhuis, A-J. (2006). Sphingolipids, ABC transporters and chemosensitivity in neuroblastoma. Groningen:
s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the











Differential expression of sphingolipids in P-glycoprotein or 
multidrug resistance-related protein 1 expressing human 
neuroblastoma cell lines 
 




1Department of Cell Biology, Section Membrane Cell Biology, University Medical 
Centre Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands 
2Department of Pathology and Laboratory Medicine, University Medical Centre 
Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands 
3Department of Paediatric Oncology and Haematology, Beatrix Children’s Hospital, 
University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen 
 
 





































The sphingolipid composition and multidrug resistance status of three human neuroblastoma 
cell lines were established. SK-N-FI cells displayed high expression and functional (efflux) 
activity of P-glycoprotein, while multidrug resistance-related protein 1 was relatively 
abundant and most active in SK-N-AS cells. These two cell lines exhibited higher 
sphingolipid levels, compared to SK-N-DZ, which had the lowest activity of either ATP-
binding cassette transporter protein. SK-N-DZ cells also differed in ganglioside composition 
with predominant expression of b-series gangliosides. In conclusion, these three 
neuroblastoma cell lines offer a good model system to study sphingolipid metabolism in 
relation to ATP-binding cassette transporter protein function. 





Treatment failure in neuroblastoma, one of the most common extracranial solid tumours in 
childhood, is often due to the occurrence of multidrug resistance (MDR). A large variety of 
MDR mechanisms exists, including the over-expression of energy-dependent drug efflux 
proteins, such as P-glycoprotein (Pgp) and multidrug resistance-related protein 1 (MRP1) 
(McKenna and Padua, 1997). 
Moreover, it has become apparent that sphingolipids and their metabolism play a role 
in drug resistance, possibly in concert with ATP-binding cassette (ABC) transporter proteins 
(Sietsma et al., 2001; Senchenkov et al., 2001; Sietsma et al., 2002). Evidence for a relation 
between MDR and sphingolipids has come from studies in tumour cell lines, which acquired a 
drug resistant phenotype by selection with cytotoxic agents. The level of glucosylceramide 
(GlcCer), a precursor of all complex glycosphingolipids and a direct metabolic product of 
ceramide (Cer), was consistently elevated in several Pgp over-expressing cell lines (Lavie et 
al., 1996). A similar GlcCer increase was observed in the MRP1 over-expressing HT29col cell 
line (Kok et al., 2000). It has even been suggested to consider increased GlcCer levels as a 
diagnostic marker for MDR tumours (Lucci et al., 1998). 
Little is known concerning the mechanisms underlying MDR-associated sphingolipid 
changes, but these may depend on cell type. It has been suggested that increased conversion 
of Cer to GlcCer by glucosylceramide synthase (GCS) in Pgp over-expressing MCF-7 cells 
rescues cells from cytostatic-induced Cer-mediated apoptosis (Liu et al., 1999; Liu et al., 
2001). On the other hand, in Pgp over-expressing 2780AD cells, uncoupling of GlcCer and 
lactosylceramide (LacCer) biosynthesis in the Golgi apparatus leads to accumulation of 
GlcCer, without changes in GCS expression or activity (Veldman et al., 2002). It is therefore 
important to explore MDR-associated changes in sphingolipid composition in a wide variety 
of tumour cells with variable expression of ABC transporter proteins. 
In this study we have characterised both the MDR status and the sphingolipid composition of 
three human neuroblastoma cell lines, SK-N-AS, SK-N-DZ and SK-N-FI. These cell lines 
offer the advantage that their MDR properties have emerged in vivo, in contrast to in vitro 
drug selection models. In the latter multiple cellular adaptations may have been co-selected. 
An additional advantage of these cell lines is their high content of complex 
glycosphingolipids, e.g. gangliosides (Kaucic et al., 2001). Although gangliosides have only 




shows GM3- and GD3-induced phosphorylation of Pgp on serine residues, thereby 
modulating its activity (Plo et al., 2002). 
Our results in these neuroblastoma cell lines show that differential neutral sphingolipid and 
ganglioside metabolism occur in a background of differential Pgp and MRP1 expression and 
activity, acquired in vivo. As such, this contributes to our knowledge of MDR-associated 
sphingolipid metabolism. In addition, this offers a good model to study the contribution of 
specific sphingolipids, including specific gangliosides, to drug resistance of tumour cells. 
 
Materials and methods 
 
Cell culture conditions 
Human neuroblastoma cell lines SK-N-AS, SK-N-DZ and SK-N-FI were purchased from the 
ATCC (Manassas, VA, USA). They were grown as adherent monolayer cultures in 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Life Technologies BV, Breda, The 
Netherlands) supplemented with 10% fetal calf serum (Bodinco, Alkmaar, The Netherlands), 
100 units/ml penicillin (Gibco), 100 µg/ml streptomycin (Gibco) and non-essential amino 
acids (Gibco), under standard incubator conditions (humidified atmosphere, 95% air, 5% 
CO2, 37ºC). 
 
Detection of Pgp and MRP1 expression by Western blot analysis 
Western blot analysis was performed as described (Kok et al., 2000). Briefly, cells were 
washed and subjected to protein content determination (Biorad, Veenendaal, The 
Netherlands). 10 µg of protein dissolved in sample buffer was heated for 5 min at 95°C 
(except MRP1 samples), loaded and run on SDS-PAGE (10%) mini-gels. Proteins were 
electrotransferred onto Immobilon-P PVDF. For detection, primary mouse anti-Pgp, C219 
(Signet-Sanbio B.V., Uden, The Netherlands), 1:300 or rat anti-MRP1, MRPr1 (Signet-
Sanbio B.V.), 1:1000 antibodies and secondary alkaline phophatase-conjugated sheep anti-
mouse (Pgp) or anti-rat (MRP1) IgG antibodies (Boehringer Mannheim GmbH, Mannheim, 
Germany) were used. Immunoreactive proteins were detected using p-nitroblue tetrazolium 
and 5-bromo-4-chloro-3-indolyl phosphate as substrates. 
 
Measurement of cellular sensitivity to cytotoxic drugs (MTT assay) 
15,000 cells/well were plated in microtiter plates. Cytostatics were added 4 h after plating. 96 
h after plating viability of the cells was determined as previously described (Carmichael et al., 
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1987). Briefly, 100 µg of MTT (Sigma, St. Louis, MO, USA) was added to each well and 
cells were incubated for 3.5 h at 37°C. Plates were then centrifuged (15 min, 900g) and the 
supernatants were removed. Pellets were dissolved in DMSO and absorbencies were 
measured in a microtiter plate reader (µQuant, Bio-Tek Instruments, Winooski, VT, USA) at 
a  of 570 nm. The background absorbency was subtracted from all values and data were 
expressed as percentage compared to untreated control cells (=100%). IC50 values (= drug 
concentration which results in viability reduction of 50%) were determined directly from the 
dose-response curves.  
 
Detection of Pgp and MRP1-mediated drug efflux by FACS analysis 
Cells (1x106 in HBSS) were incubated for 60 min at 37°C in the presence of the Pgp substrate 
Rhodamine 123 (Rh123, 10 µM, Sigma) or the MRP1 substrate 5-carboxyfluorescein 
diacetate (CFDA, 0.5 µM, Sigma) and in the presence “(+/+)” or absence “(-/-)” of the Pgp 
inhibitor cyclosporin A (CSA, 10 µM, Alexis, Carlsbad, CA, USA) or the MRP1 inhibitor 
MK571 (20 µM). After loading, cells were washed with ice-cold buffer and incubated for 60 
min (Pgp) or 45 min (MRP1) at 37°C (efflux) in the presence (+/+) or absence (-/-) of 
inhibitor. Subsequently, efflux was stopped by replacement with ice-cold buffer and 
Rh123/CF fluorescence was measured by flow cytometry (FACSCalibur; Becton Dickinson, 
Franklin Lakes, NJ, USA). For each sample 5,000 events were collected and analysed using 
Win-list 5.0 software (Verity Software House Inc., Topsham, ME, USA), which resulted in 
median relative Fluorescence Units (F.U.). From these data the efflux-blocking factor (BF) 
was calculated, which is defined as: 
 
 [F.U. in (+/+) cells – F.U. in untreated cells] 
BF =  
 [F.U. in (-/-) cells – F.U. in untreated cells] 
 
Equilibrium radiolabelling and analysis of cellular sphingolipids 
Sphingolipid pools were metabolically radiolabelled to equilibrium as described (Veldman et 
al., 2002). Cells were grown for 48 h in the presence of L-[U-14C]serine (1 µCi/ml; 
Amersham International, Bercks, UK), harvested and subjected to lipid extraction (Bligh and 
Dyer, 1959). Acylglycerolipids were hydrolysed during a 1 h incubation at 37°C in 
CHCl3/CH3OH (1:1, v/v) containing NaOH (0.1 M). The remaining lipids were re-extracted 




Amsterdam, The Netherlands). Plates were developed in CHCl3/CH3OH/H2O (14:6:1, v/v/v) 
in the first dimension and in CHCl3/CH3COOH (9:1, v/v) in the second dimension. After 
scraping of the Cer containing spots, the plates were sprayed with 2.5% H3BO3 (w/v) in 
CH3OH and developed once more in the second dimension, this time using 
CHCl3/CH3OH/25% (w/v) NH4OH (13:7:1, v/v/v) as the mobile phase. GlcCer, 
galactosylceramide (GalCer), LacCer, and sphingomyelin (SM) containing spots were scraped 
from the plates. Radioactivity was measured by scintillation counting (Packard Topcount 
microplate scintillation counter, Meriden, CT, USA). Lipid levels were expressed as dps 
incorporated in a specific lipid species per 103 dps of total lipid-incorporated radioactivity, as 
measured after the initial lipid extraction. 
 
Measurement of C5-Bodipy-labelled sphingolipids 
Cells were washed three times with HBSS and incubated in the presence of C5-Bodipy-
ceramide (4 µM; Molecular Probes Europe BV, Leiden, The Netherlands) at 37°C for 3 h. 
After washing, cells were scraped, the protein content was determined and lipids were 
extracted (Bligh and Dyer, 1959). Extracted lipids were applied to HPTLC plates and run in 
CHCl3/CH3OH/NH4OH/H2O (60:40:4:1; v/v/v/v). Individual spots were scraped, suspended 
in a 1% (v/v) Triton X-100 solution (2 ml), and shaken vigorously for 1 h. After 
centrifugation, fluorescence in the supernatants was measured (λex = 505 nm; λem = 511 nm; 
SLM Aminco SPF-500, Urbana, IL, USA), by reference to a standard curve of a known 
amount of C5-Bodipy-Cer.  
  
Mass analysis of gangliosides 
Gangliosides were isolated from 5-7 x 107 cells, as described (Senn et al., 1989; Ladisch and 
Gillard, 1985). Briefly, pelleted cells were extracted in CHCl3/CH3OH (1:1; v/v) and 
CHCl3/CH3OH (2:1; v/v). Pooled supernatants were dried (N2) and the lipids were dissolved 
and sonicated in CHCl3/CH3OH (1:1; v/v). After centrifugation and overnight storage at -
20°C, the supernatant was dried, dissolved in diisopropylether/1-butanol (3:2; v/v), and 17 
mM NaCl was added. The aqueous phase was re-extracted with diisopropylether/1-butanol 
and subsequently lyophilised. Samples were dissolved in CH3OH/H2O (1:1; v/v) and loaded 
onto pre-washed Sep-Pak C18 (Waters, Milford, MA, USA) cartridges. After rinsing (H2O), 
gangliosides were eluted with CH3OH and CHCl3/CH3OH (1:1; v/v). The eluate was 
concentrated and loaded onto HPTLC plates, which were developed in CHCl3/CH3OH/0.2% 
(w/v) CaCl2 (11:9:2; v/v/v) and stained with Ehrlich reagent (Partridge, 1948). Gangliosides 
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were quantified by densitometry, involving analysis with Scion Image Beta 4.0.2 (Scion 
Corporation, Frederick, MD, USA) software of a scanned image of the HPTLC. 
 
Statistical analysis 
Results are presented as mean ± S.D. (n ≥ 4). Statistical analysis was performed with the 




Differential Pgp and MRP1 expression and efflux activity in SK-N-FI, SK-N-DZ and SK-N-AS 
Western blotting analysis revealed the relative expression levels of Pgp and MRP1 in three 
human neuroblastoma cell lines (Fig. 1). Pgp expression was high in SK-N-FI, and hardly 
expressed in SK-N-AS. In contrast, MRP1 expression was highest in SK-N-AS and lowest in 
the SK-N-FI. SK-N-DZ displayed intermediate levels of both ABC transporters. In 
accordance, significant (Rh123) efflux activity of Pgp was observed in SK-N-FI cells only 
(Table I). Moreover, significant functional activity of MRP1 was found in SK-N-AS, while 
SK-N-FI and SK-N-DZ displayed residual efflux activity.  
 
Functional activity of ABC transporters is correlated with resistance to multiple cytotoxic drugs 
The impact of functional (efflux) activity of ABC transporters on drug resistance was 
explored by means of cytotoxicity assays. The three cell lines were exposed to paclitaxel, 
vincristine, etoposide and doxorubicin, which have all been recognised as Pgp substrates. 
Accordingly, the Pgp expressing SK-N-FI displayed relatively high resistance to all four 
Figure 1. Western blot of relative Pgp or MRP1 expression levels in human neuroblastoma cell lines. 
Equal amounts of protein were loaded on the gel. The sizes of the Pgp and MRP1 proteins are 170 





cytostatic drugs, with high IC50 values (Table II). The MRP1 expressing SK-N-AS was less 
resistant even though MRP1 is able to transport vincristine, etoposide and doxorubicin. Least 
resistance was displayed by SK-N-DZ, which lacked significant functional activity of either 
Pgp or MRP1. 
In conclusion, the highest expression levels and activities of Pgp and MRP1 were found in the 
SK-N-FI and SK-N-AS cell lines, respectively. This expression correlated well with the 
degree of drug resistance displayed by these neuroblastoma cell lines, compared to SK-N-DZ, 
and suggests a prominent role for ABC transporters, especially Pgp, in drug resistance of 
these cell lines. 
 Paclitaxel (nM) Vincristine (ng/ml) Etoposide (ng/ml) Doxorubicin (nM) 
SK-N-AS 6.8 ± 3.5 0.8 ± 0.3     875 ± 114 291 ± 72 
SK-N-DZ 2.0 ± 0.1 0.9 ± 0.2 213 ± 6 85 ± 5 
SK-N-FI > 50 >30 >1000 >1000 
 
Analysis of the sphingolipid composition in SK-N-AS, SK-N-DZ and SK-N-FI cells 
Sphingolipid biosynthesis was studied by incubating the cells with C5-Bodipy-Cer. A 
relatively high conversion to both C5-Bodipy-GlcCer and C5-Bodipy-SM was observed in 
both SK-N-FI and SK-N-AS, as compared to SK-N-DZ (Table IIIA). The high conversion to 
C5-Bodipy-SM correlated well with high endogenous levels of SM in SK-N-FI and especially 
SK-N-AS, as measured by equilibrium radiolabelling (Table IIIB). Endogenous GlcCer, 
which is known to be associated with MDR, is more abundant as well in the resistant SK-N-
FI and SK-N-AS, as compared to the relatively chemosensitive SK-N-DZ.  
 BF   P-values 
 Pgp MRP1   Pgp MRP1 
SK-N-AS 2.2 ± 0.4 26.7 ± 18.2        AS v DZ 0.02 0.03 
SK-N-DZ 1.7 ± 0.3 5.3 ± 2.9      AS v FI <0.001 0.01 
SK-N-FI 86.0 ± 23.9 8.5 ± 2.6      DZ v FI <0.001 0.07 
Table I. Efflux blocking factors for Pgp and MRP1 in human neuroblastoma cell lines 
Cells were loaded with either Rh123 (10 µM) or CFDA (0.5 µM) for 60 min at 37°C or 10°C, 
followed by efflux in the presence or absence of the inhibitors CSA (10 µM) or MK571 (20 µM) for 
60 min or 45 min at 37°C. Blocking factors (BF) were calculated as described in ‘Materials and 
methods’. Data represent the mean ± S.D. of 4 independent experiments. 
Table II. IC50 values for paclitaxel, vincristine, etoposide and doxorubicine as 
determined with the MTT cell survival assay 
SK-N-AS, SK-N-DZ and SK-N-FI were exposed to increasing concentrations of paclitaxel (0-50 
nM), vincristine (0-30 ng/ml), etoposide (0-1000 ng/ml) and doxorubicine (0-1000 nM) for 96 h. 
Data represent the mean ± S.D. of ≥ 4 independent experiments, each consisting of two replicate 
determinations. 
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Table III. Sphingolipid metabolism and composition of SK-N-FI, SK-N-DZ and SK-
N-AS, as determined with the use of C5-Bodipy-Cer and L-[U-14C]serine, respectively 
(A) Cells were incubated with C5-Bodipy-Cer (4 µM) for 3 h and lipids were isolated and analysed. 
The amounts of newly synthesised C5-Bodipy-GlcCer and C5-Bodipy-SM were calculated in nmol 
lipid/mg protein from 6 independent experiments. (B) Cells were incubated with L-[U-14C]serine (1 
µCi/ml) for 48 h and sphingolipids were isolated and analysed. Values are expressed as dps of a 
specific sphingolipid per 1000 dps of the total radiolabelled lipid pool. Data represent the mean ± 
S.D. of 4 independent experiments. 
The three cell lines were also analysed for their ganglioside composition (Fig. 2). High levels 
of a-series (i.e. GM3, GM2, GM1 and GD1a) gangliosides were found in the SK-N-FI (Fig. 
2A) and SK-N-AS (Fig. 2B). In contrast, the SK-N-DZ (Fig. 2C) expressed predominantly b-
series gangliosides (GD3, GD2, GD1b and GT1b). 
C5-Bodipy-labelled lipids A SK-N-FI SK-N-DZ SK-N-AS 
GlcCer 29.9 ± 5.9 17.1 ± 1.3 27.0 ± 7.4 
SM 27.3 ± 2.7 19.5 ± 5.7   65.8 ± 15.1 
Radiolabelled lipids B SK-N-FI SK-N-DZ SK-N-AS 
Cer 12.9 ± 2.3   9.8 ± 1.0   7.4 ± 1.0 
GlcCer 10.1 ± 1.1   4.2 ± 1.3   8.2 ± 0.9 
LacCer 11.6 ± 1.9   4.0 ± 0.6   1.8 ± 0.2 
GalCer   1.7 ± 0.4   0.8 ± 0.4   1.4 ± 0.1 
SM 45.0 ± 1.2 16.6 ± 5.1 74.1 ± 7.2 
Figure 2. (A), (B) and (C) show the ganglioside patterns of the human neuroblastoma cell lines SK-
N-FI, SK-N-DZ and SK-N-AS, respectively. Reference gangliosides (ref) and the relative amount of 
gangliosides per cell line are displayed next to these patterns. Ganglioside quantification was done 
by densitometry. The cell lines SK-N-FI (89%) and SK-N-AS (79%) predominantly express a-series 
gangliosides (GM3, GM2, GM1 and GD1a), while b-series gangliosides (GD3, GD2, GD1a and 
GT1b) are the major products (62%) of the SK-N-DZ cell line. Gangliosides were isolated from 







It has been shown that in vitro established Pgp (Lavie et al., 1996; Veldman et al., 2002) and 
MRP1 (Kok et al., 2000) over-expressing tumour cell lines display enhanced levels of the 
sphingolipid GlcCer. Moreover, these studies showed that in addition to changes in the level 
of GlcCer, other sphingolipid levels are altered in MDR tumour cells, however in a cell type 
dependent fashion. In the present study, we analysed the composition and metabolism of 
sphingolipids in neuroblastoma cell lines, which differ from the previously studied models in 
the sense that MDR acquisition and ABC transporter expression were attained in vivo, and 
thus more resemble naturally occurring adaptations. In this model, an enhanced GlcCer level 
also parallels expression of functionally active ABC transporters, and additional changes in 
sphingolipid composition occur as well. A novel finding in the current model is that 
expression of ABC transporters is correlated with overall enhanced levels and biosynthesis of 
sphingolipids, while a dichotomy is observed with respect to the biosynthetic pathway of 
choice. Although Pgp is expressed in all three neuroblastoma cell lines, it is functionally 
active only in SK-N-FI and this is correlated with channelling of sphingolipid metabolism 
into glycolipids. MRP1 is also expressed in all three cell lines, but functional activity only 
occurs in SK-N-AS. The latter is correlated with channelling of sphingolipid metabolism 
towards SM biosynthesis. A direct causal relationship between sphingolipid metabolism and 
ABC transporter expression/function remains to be proven. With respect to the downstream 
metabolic products of GlcCer, such as gangliosides, differences were also observed between 
functionally active ABC transporter expressing neuroblastoma cells and SK-N-DZ cells. The 
high expression of GD2, as occurs in SK-N-DZ, is generally associated with more aggressive 
forms of neuroblastoma, but relations to drug resistance are unknown. A functional role for 
gangliosides in MDR is only recently emerging. Certain gangliosides (GM3, GD3) may be 
directly involved in MDR by modulation of Pgp function through alteration of its 
phosphorylation state (Plo et al., 2002). Consistent with this notion, our preliminary results in 
the SK-N-AS cell line show that long-term (5 days) inhibition of glycolipid synthesis by 
incubation with 1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol results in a 30% 
decrease of MRP1-mediated CF efflux (data not shown). Recently, up-regulation of 
ganglioside biosynthesis at the level of GM3 biosynthesis was shown to occur in fenretinide-
adapted A2780 cells, and was correlated with fenretinide resistance (Prinetti et al., 2003). Due 
to the novelty of this particular research area and the limited studies and results available, a 
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consistent picture concerning the contribution of specific gangliosides to MDR has not yet 
emerged.  
 In conclusion, the three neuroblastoma cell lines characterised in this study offer a 
good model to further dissect the roles of specific sphingolipids and their metabolism in MDR 
at various levels of sphingolipid metabolic pathways and against a background of either one 
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